5-Amino-1MQ

5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), the clearance enzyme that methylates nicotinamide to 1-methylnicotinamide (1-MNA). It is not a peptide; as a small molecule it survives gastrointestinal transit intact, which makes an oral route viable alongside subcutaneous administration.

It was developed by researchers at the University of Texas Medical Branch working on obesity and metabolic dysfunction. In diet-induced obese mice, treatment produced substantial adipose loss with no reduction in food intake — the effect is entirely on the expenditure side, mechanistically distinct from GLP-1 receptor agonists such as semaglutide or retatrutide.

Positioning covers fat loss, longevity and athletic performance, with the visceral compartment specifically named, and with insulin sensitivity, mitochondrial function and cellular repair as secondary claims. Earlier material also attributes CD38 inhibition to the compound as a second route to NAD+ preservation alongside the NNMT mechanism.

Regulatory and evidentiary status: research compound, not FDA approved, no published human clinical trials. All efficacy data is preclinical — animal models and in vitro work. Awosemo et al. (2021) established 38.4% oral bioavailability in rats with a terminal half-life of 6.90 hours.

Administration for this route is subcutaneous, once daily in the morning. An oral capsule form exists — see the oral entry; the dose ranges for the two routes overlap because subcutaneous bypasses first-pass losses.

NAD+ is the electron carrier feeding the electron transport chain; reduction to NADH, electron delivery, and regeneration back to NAD+ cycle thousands of times daily per cell, and ATP output is gated on NAD+ availability. Roughly 80% of NAD+ production runs through the salvage pathway, recycling nicotinamide (vitamin B3) back to NAD+ via NAMPT.

NNMT is the opposing arm: it methylates nicotinamide to 1-MNA for excretion, consuming SAM as the methyl donor. Two pathways therefore compete for one substrate. In liver, where NNMT is strongly expressed, redundant NAD+ synthetic routes buffer this. Adipose tissue has no such buffer — NAD+ synthesis there depends primarily on the salvage pathway, and NNMT is the only catabolic enzyme for nicotinamide in fat. Obesity-driven NNMT overexpression in white adipose tissue therefore creates a self-reinforcing loop: raised NNMT depletes adipocyte NAD+, impairing oxidation and favouring storage, which raises NNMT further. Kraus et al. (2014) identified NNMT as the most strongly reciprocally regulated gene in white adipose tissue in metabolic dysfunction models.

Inhibition with 5-Amino-1MQ reduces intracellular 1-MNA, raises intracellular NAD+ and SAM, activates SIRT1 downstream of the NAD+ rise, suppresses lipogenesis, reduces adipocyte size, and increases energy expenditure with food intake unchanged (Neelakantan et al., 2018). The mechanism is expenditure-side only; there is no incretin or appetite component.

One caveat sits in the enzyme kinetics: NAMPT has 430 times higher affinity for nicotinamide than NNMT does, so under normal conditions nicotinamide preferentially flows toward NAD+ synthesis regardless. NNMT becomes a meaningful drain only when massively overexpressed — which is why the target population is defined by adipose NNMT overexpression rather than by age.

Adipose: approximately 35% reduction in white adipose tissue mass and 30% decrease in adipocyte size in diet-induced obese mice, with food intake unchanged; suppression of lipogenesis and lowered plasma total cholesterol (Neelakantan et al., 2018). Babula et al. (2024) reported dose-dependent limitation of body weight and fat mass gains.

Lean tissue: preservation of lean mass through the loss phase, attributed to raised NAD+ and SIRT1 activation supporting protein retention and reducing catabolism — a contrast with caloric restriction alone.

Glycaemic: improved oral glucose tolerance and insulin sensitivity, suppression of hyperinsulinaemia (Babula et al., 2024).

Hepatic: improved liver pathology markers in obese mice, including fatty liver changes accompanying obesity (Babula et al., 2024).

Skeletal muscle: activation of senescent muscle stem cells and improved regenerative capacity of aged skeletal muscle, with peak torque up approximately 70% versus controls (Neelakantan et al., 2019) — the first demonstration that NNMT inhibition rescues age-related muscle stem cell deficits.

Microbiome and composition: combined with a high-fat to low-fat diet switch, body weight and fat mass normalised to levels indistinguishable from never-obese mice, which diet switch alone could not achieve; gut microbiome shifted with increased Lactobacillus and decreased Erysipelatoclostridium (Dimet-Wiley et al., 2022).

NAD+ and longevity: NAD+ underpins mitochondrial ATP production and declines with age, impairing cellular energy production. Earlier material attributes CD38 inhibition as an additional NAD+-preserving route and frames this as the longevity rationale.

Claims carried from earlier material, without preclinical citation here: possible mitochondrial biogenesis; possible neuroprotection against age-related neurodegeneration (Alzheimer's, Parkinson's) via improved mitochondrial health and NAD+ availability; improved cerebral energy metabolism supporting cognition and reducing brain fatigue; improved endurance and exercise capacity through enhanced mitochondrial activity and fat oxidation; possible reduction in inflammation and oxidative stress.

No human clinical data exists on response timelines; what follows is mechanistic reasoning plus aggregated user report.

Patient selection dominates the expected outcome. NNMT overexpression correlates with adiposity rather than with age (Kraus et al., 2014). Preclinical efficacy was generated in diet-induced obese models with pre-existing NNMT elevation, where inhibition corrected an established dysfunction. In lean phenotypes, adipose NNMT sits at baseline, there is no pathological drain on the salvage pathway, and there is correspondingly little to correct.

Typical reported course: subtle increase in baseline energy and thermogenesis within 1 to 2 weeks; measurable fat loss, where it occurs, around weeks 3 to 4. The effect is expenditure-mediated and slow to translate into visible change.

At 50 to 100 mg daily, users report modest but measurable loss over 4 to 6 week cycles, typically 3 to 6 pounds with diet and training constant, described as gradual. Appetite is consistently reported unchanged, consistent with the mechanism — there is no incretin component and no GLP-1-like hunger suppression.

Microdose protocols at 150 to 600 mcg per day generally produce minimal to no reported effect; any subjective improvement is difficult to distinguish from placebo at roughly 400-fold below the IC50 threshold.

In practice, response is best in subjects carrying significant excess body fat, particularly those already on GLP-1 agonists such as retatrutide or tirzepatide, where the expenditure-side mechanism layers onto appetite suppression without overlap. Reported response in lean subjects is markedly weaker, consistent with the mechanism.

No published human dose-finding studies exist. The protocol is extrapolated from animal data, pharmacokinetic modelling and practice patterns.

Subcutaneous: 50 to 100 mg daily, morning only. SubQ bypasses first-pass losses, so a given dose delivers more to plasma than the oral equivalent; the subcutaneous dose can sit slightly below the oral dose and achieve similar or better exposure. The oral protocol for reference is 50 to 100 mg daily, 50 mg for week one then 100 mg if tolerated, with approximately 38% bioavailability (Awosemo et al., 2021 reported 38.4% in rats, terminal half-life 6.90 hours). The 50 to 100 mg daily regimen needs a far larger vial than the 10 mg size used for the older protocols below; match the vial to the dose before reconstituting.

Timing: morning only. Increased cellular energy expenditure and raised NAD+ are stimulatory; later dosing can disrupt sleep.

Cycling: 4 to 6 weeks on, 2 to 4 weeks off, 2 to 3 cycles total with reassessment after each. Continuous NNMT inhibition may provoke adaptive responses that reduce effectiveness, and as adiposity falls NNMT overexpression falls with it, so subsequent cycles yield diminishing returns.

On dose rationale. Allometric scaling of the Neelakantan et al. (2018) mouse dose translates to roughly 400 mg per day in humans. Published recommendations span 150 to 600 mcg per day up to 50 to 150 mg per day — a 2,500-fold spread. Using metformin as a structural analogue (comparable molecular weight, charge, oral bioavailability and half-life), pharmacokinetic analysis puts 50% NNMT inhibition at roughly 50 to 100 mg per day and near-complete inhibition at 400 to 600 mg per day. Microdoses of 150 to 600 mcg per day sit approximately 400-fold below the IC50 threshold; the lowest concentration producing any NAD+ increase in research was about 1,000 times higher than microdoses achieve. The legacy subcutaneous ladders in the 1 to 5 mg per day range likewise fall below the modelled effective window.

Kinetic argument against microdosing: NAMPT has 430-fold higher affinity for nicotinamide than NNMT, so flux favours NAD+ synthesis by default unless NNMT is massively overexpressed. For NAD+ support per se, a direct precursor (NMN) or injectable NAD+ is the more coherent choice than a sub-threshold enzyme inhibitor.

Economics explain the persistence of low-dose protocols: a 10 mg vial at 150 mcg per day lasts about 66 days, the same vial at 5 mg per day lasts 2 days. The effective dose is rarely tested outside funded trials.

Practical adjuncts carried from earlier material: maintain hydration and balanced meals through the cycle, reduce the dose on fatigue or nausea, and note that dosing alongside a light meal has been offered as gastrointestinal side-effect mitigation.

Solid preclinical dataset, no human clinical evidence. No published human trials; not FDA-approved for human use. All efficacy data is preclinical and in vitro.

Neelakantan et al. (2018), Biochemical Pharmacology — the foundational study. 5-Amino-1MQ reduced intracellular 1-MNA, increased intracellular NAD+ and SAM, and suppressed lipogenesis in adipocytes. In diet-induced obese mice it significantly reduced body weight, white adipose mass and adipocyte size, and lowered plasma total cholesterol, without impacting food intake or producing observable adverse effects. Allometric translation to humans came to roughly 400 mg per day.

Kraus et al. (2014), Nature — biological foundation. NNMT is the most strongly reciprocally regulated gene in white adipose tissue in metabolic dysfunction models. NNMT knockdown prevented diet-induced obesity and improved insulin resistance; expression was elevated in white adipose tissue and liver of obese and diabetic mice. This is the study demonstrating that NNMT overexpression correlates more with body fat than with ageing.

Neelakantan et al. (2019), Biochemical Pharmacology — aged skeletal muscle. 5-Amino-1MQ activated senescent muscle stem cells and improved regenerative capacity of aged muscle; peak torque increased approximately 70% versus controls. First demonstration that NNMT inhibition rescues age-related muscle stem cell deficits.

Dimet-Wiley et al. (2022), Scientific Reports — 5-Amino-1MQ plus a high-fat to low-fat diet switch in DIO mice normalised body weight and fat mass to levels indistinguishable from never-obese mice, which diet switch alone could not achieve. Microbiome shifted beneficially: increased Lactobacillus, decreased Erysipelatoclostridium.

Babula et al. (2024), Diabetes, Obesity and Metabolism — pharmacokinetics and metabolic effects. Dose-dependently limited body weight and fat mass gains, improved oral glucose tolerance and insulin sensitivity, suppressed hyperinsulinaemia, and improved liver pathology markers.

Awosemo et al. (2021), Journal of Pharmaceutical and Biomedical Analysis — 38.4% oral bioavailability in rats, terminal half-life 6.90 hours.

Limitations: all efficacy data from animal models; practical dosing is extrapolated from allometric scaling and pharmacokinetic modelling rather than human dose-finding; no long-term human safety data.

Dose rationale. IC50 coverage — blocking at least 50% of the target enzyme — is the threshold for meaningful effect. Pharmacokinetic analysis using metformin as a structural analogue (similar molecular weight, charge, oral bioavailability and half-life) puts 50% NNMT inhibition at roughly 50 to 100 mg daily and near-complete inhibition at 400 to 600 mg daily. Microdoses of 150 to 600 mcg daily sit roughly 400 times below the 50% threshold. Separately, NAMPT has 430 times higher affinity for nicotinamide than NNMT does, so nicotinamide preferentially flows toward NAD+ synthesis under normal conditions; NNMT only becomes a meaningful drain when massively overexpressed.